Published On: Mon, Jun 19th, 2017

Galectin Therapeutics Inc. (GALT) Broker Views On Wall Street


A number of investment brokers have recently updated their price targets on shares of Galectin Therapeutics Inc. (GALT).

Most recent broker ratings

04/03/2017 – Galectin Therapeutics Inc. had its “market perform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 2 price target on the stock.

03/30/2017 – Galectin Therapeutics Inc. was upgraded to “buy” by analysts at H.C. Wainwright. They now have a USD 3.5 price target on the stock.

09/28/2016 – Galectin Therapeutics Inc. was downgraded to “sell” by analysts at Roth Capital. They now have a USD 0.75 price target on the stock.

08/12/2015 – Galectin Therapeutics Inc. had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 16 price target on the stock.

08/01/2014 – Galectin Therapeutics Inc. was downgraded to “hold” by analysts at Aegis Capital.

07/29/2014 – Galectin Therapeutics Inc. had its “positive” rating reiterated by analysts at BMO Capital Markets.

10/07/2013 – Ascendiant Capital Markets began new coverage on Galectin Therapeutics Inc. giving the company a “buy” rating. They now have a USD 13 price target on the stock.

The share price of Galectin Therapeutics Inc. (GALT) was down -5.62% during the last day of trading, with a day high of 2.55. 299689 shares were traded during the last session.

The stock’s 50 day moving average is 2.59 and its 200 day moving average is 1.87. The stock’s market capitalization is 81.47M. Galectin Therapeutics Inc. has a 52-week low of 0.49 and a 52-week high of 3.68.

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.